Forest Gets Untitled Letter After Reps Tout Weight Loss Adverse Event as Potentially Beneficial

Drug Industry Daily
Forest Laboratories has been hit with an untitled letter after two of its sales reps implied that weight loss while using Daliresp tablets — listed as an adverse reaction — could be beneficial for overweight chronic obstructive pulmonary disease (COPD) patients.

To View This Article:


Subscribe To Drug Industry Daily